期刊
TUBERCULOSIS
卷 85, 期 5-6, 页码 415-420出版社
CHURCHILL LIVINGSTONE
DOI: 10.1016/j.tube.2005.08.009
关键词
solid lipid nanoparticles; drug delivery; antitubercular drugs; tuberculosis; chemotherapy
The present study was planned to evaluate the chemotherapeutic potential of oral solid lipid nanoparticles (SLNs) incorporating rifampicin, isoniazid and pyrazinamide against experimental tuberculosis. The SLNs were prepared by the emulsion solvent diffusion technique with an encapsulation efficiency of 51 +/- 5% for rifampicin, 45 +/- 4% for isoniazid and 41 +/- 4% for pyrazinamide. Following a single oral administration to mice, therapeutic drug concentrations were maintained in the plasma for 8 days and in the organs (lungs, liver and spleen) for 10 days whereas free drugs were cleared by 1-2 days. In M. tuberculosis H(37)Rv infected mice, no tubercle bacilli could be detected in the lungs/spleen after 5 oral doses of drug loaded SLNs administered at every 10th day whereas 46 daily doses of oral free drugs were required to obtain an equivalent therapeutic benefit. Thus, SLN based antitubercular drug therapy forms a sound basis for reducing dosing frequency and improving patient compliance for better management of tuberculosis. (c) 2005 Published by Elsevier Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据